Bictegravir news

All news on Bictegravir (also known as GS-9883): plants, production capacities, investments and involved companies.

25 February 2026

ViiV Healthcare Unveils Data on Twice-Yearly HIV Treatments

VH184 and VH499 show promise for twice-yearly HIV treatment, with improved resistance and tolerability, reducing the need for daily medication.
25 February 2026

Merck Presents Phase 3 Trial Results for HIV-1 Treatment DOR/ISL at CROI 2026

DOR/ISL shows non-inferiority and similar safety to BIC/FTC/TAF in HIV-1 treatment-naïve adults and maintains suppression in those switching from other therapies.
19 November 2025

Merck Reports Positive Phase 3 Trial Results for HIV-1 Treatment DOR/ISL

DOR/ISL shows non-inferiority to BIC/FTC/TAF in HIV-1 treatment-naïve adults, meeting efficacy and safety goals. Detailed findings to be presented at a future scientific congress.
15 October 2025

Merck Reports Phase 3 Trial Data on Doravirine-Islatravir Regimen

Phase 3 trials show minimal weight, body composition, and lipid changes with the DOR/ISL regimen in HIV-1 patients, maintaining viral suppression without resistance.

Who will be producing Bictegravir in the future?

Find out with chemXplore Alpha

Learn more